Notes to Condensed Consolidated Financial Statements
(Unaudited)
(in thousands, except share data or otherwise stated)
1.Nature of Operations and Organization
Oklo Inc. conducts its operations through its subsidiary Oklo Technologies, Inc., a Delaware corporation incorporated on July 3, 2013.
The Company is developing advanced fission power plants to provide clean, reliable, and affordable energy at scale and plans to commercialize its metal-fueled fast reactor technology with the Aurora powerhouse product line. The Aurora product line is designed to produce up to 15 and 75 megawatts of electricity (“MWe”) on fresh, recycled, or down-blended nuclear fuel. Oklo’s advanced fission technology has a history of successful operation, first demonstrated by the Experimental Breeder Reactor-II (“EBR-II”), which sold and supplied power to the grid and showed effective used nuclear fuel recycling capabilities over 30 years of operation. The Company is also commercializing nuclear fuel recycling technology that can convert used nuclear fuel into usable fuel for its reactors. Furthermore, Oklo has achieved several significant deployment and regulatory milestones, including securing a site use permit from the U.S. Department of Energy (“DOE”) for the Idaho National Laboratory (“INL”) Site and a fuel award of five metric tons of HALEU produced from recovered uranium from previously irradiated EBR-II fuel from INL for a commercial-scale advanced fission power plant in Idaho. On August 13, 2025, Oklo and its wholly owned subsidiary Atomic Alchemy Inc. (“Atomic Alchemy”) (as further described below) were selected by the DOE for three of the eleven awarded projects under the recently formed Reactor Pilot Program (“RPP”). Oklo will participate in two of the RPP projects and Atomic Alchemy will participate in one. Under the RPP, participants will demonstrate advanced reactor projects aiming to reach criticality by July 4, 2026 or as soon as possible thereafter.
On May 9, 2024, the Company consummated a business combination pursuant to an Agreement and Plan of Merger and Reorganization dated July 11, 2023 (as amended, modified, supplemented, or waived, the “Merger Agreement”), by and between AltC Acquisition Corp. (“AltC”) and Oklo Technologies, Inc. (the “Recapitalization”). Prior to the Recapitalization, Oklo Technologies, Inc. was formerly known as Oklo Inc. (referred to herein as “Legacy Oklo”). Upon consummation of the Recapitalization, AltC changed its name to Oklo Inc. See Note 3 — Business Combination — Recapitalization for additional information.
In connection with the Recapitalization consummated on May 9, 2024 that was accounted for as a reverse recapitalization, where Legacy Oklo was determined to be the accounting acquirer, the common stock has been recast to reflect the retroactive application of the reverse recapitalization. Under this method of accounting, AltC was treated as the “acquired” company for financial reporting purposes. Accordingly, for accounting purposes, the Recapitalization was treated as the equivalent of Legacy Oklo issuing stock for the net assets of AltC, accompanied by a recapitalization. Results of operations prior to the Recapitalization are presented as belonging to Legacy Oklo. The Recapitalization had no effect on reported net loss, cash flows, or total assets as previously reported. See Note 3 — Business Combination — Recapitalization for additional information.
On February 28, 2025, the Company entered into a stock purchase agreement pursuant to which it acquired 100% of the common stock outstanding of Atomic Alchemy, by way of statutory merger, to combine Oklo’s expertise in building and operating fast reactors and nuclear fuel recycling with Atomic Alchemy’s expertise in its radioisotope business to meet the increasing demands for radioisotopes in medical, energy, industry, defense, and artificial intelligence applications. See Note 3 — Business Combination — Atomic Alchemy for additional information.
Liquidity and Capital Resources
As of September 30, 2025, the Company’s cash, cash equivalents, and marketable debt securities were $1,183,563. The Company continues to incur significant operating losses. For the nine months ended September 30, 2025, the Company had a net loss of $64,217, loss from operations of $82,198, and net cash used in operating activities of $48,745. As of September 30, 2025, the Company had an accumulated deficit of $199,326.
The Company expects to utilize its existing cash, cash equivalents, and marketable debt securities to fund construction of its powerhouses, radioisotopes business, operations, and growth plans and believes that its existing cash, cash equivalents,
and marketable debt securities will be sufficient to fund its operations for the one-year period following the issuance date of these unaudited condensed consolidated financial statements.
2.Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial reporting.
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Articles 8 and 10 of Regulation S-X. Certain information or footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, it does not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. The information herein should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which was filed on March 24, 2025. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair statement of the financial position, operating results, and cash flows for the periods presented.
In addition, since the Company changed its presentation in its Form 10-K to rounding to the nearest whole number in thousands of reported amounts, the third quarter amounts for 2024 have been rounded accordingly, or as otherwise designated. This change is not material and does not impact the comparability of the Company’s unaudited condensed consolidated financial statements.
Segment Information
The Company has viewed its financial information on an aggregate basis for the purposes of evaluating financial performance and allocating the Company’s resources. The Company’s principal business consists primarily of research and development activities for its planned powerhouses, radioisotopes business, and nuclear fuel recycling and fabrication facilities. Accordingly, the Company has determined that it operates in one reportable segment. See Note 13 — Segment Information for more information about the Company’s single operating and reportable segment.
Principles of Consolidation
The unaudited condensed consolidated financial statements include the Company’s accounts and those of its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated. For further details, see Note 1 — Nature of Operations and Organization.
Use of Estimates
Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments, and assumptions that affect the amounts reported and disclosed in the unaudited condensed consolidated financial statements and accompanying notes. Actual results could differ materially from these estimates. On an ongoing basis, the Company evaluates its estimates, including those related to the valuation of the operating lease liabilities and operating right-of-use assets, useful lives of property and equipment, stock-based compensation expense, valuation allowance on deferred tax assets, and fair value of acquired intangible assets and goodwill. These estimates, judgments, and assumptions are based on current and expected economic conditions, historical data, and experience available at the date of the accompanying unaudited condensed consolidated financial statements, and various other factors that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities.
Risk and Uncertainties
The Company is subject to continuing risks and uncertainties in connection with the current macroeconomic environment, including as a result of inflation, instability in the global banking system, trade policy (including tariffs, export controls,
and sanctions), and geopolitical factors, including the ongoing conflicts in Ukraine and Israel. At this point, the extent to which these effects may impact the Company’s future financial condition or results of operations is uncertain, and as of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require the update of any estimates or judgments or an adjustment of the carrying value of any assets or liabilities. Given the nature of the business, the ongoing conflicts in Ukraine and Israel have not had an identifiable impact on the Company’s financial performance. These estimates may change as new events occur and additional information is obtained and will be recognized in the financial statements as soon as they become known.
Net Loss Per Common Share
The Company’s basic net loss per share of common stock is computed based on the average number of outstanding shares of common stock for the period, by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive securities. Diluted net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock and common share equivalents of potentially dilutive securities outstanding for the period. Potentially dilutive securities include common stock equivalents. Since the Company was in a loss position for the periods presented, basic net loss per share of common stock is the same as diluted net loss per share of common stock since the effects of potentially dilutive securities are antidilutive.
The outstanding potentially dilutive common stock equivalents as of September 30, 2025 and 2024 for: (1) options to purchase shares of common stock of 7,180,744 and 10,432,749, respectively, (2) unvested restricted stock of 640,125 and none, respectively, and (3) unvested restricted stock units of 2,354,961 and 1,284,062, respectively, have been excluded from the calculation of diluted net loss per common share due to their anti-dilutive effect.
Emerging Growth Company Status
The Company is an emerging growth company (“EGC”) as defined in the Jumpstart Our Business Startups Act (“JOBS Act”). The JOBS Act provides emerging growth companies with certain exemptions from public company reporting requirements, including reduced executive compensation disclosures and exemption from the auditor attestation requirements from Section 404(b) of the Sarbanes-Oxley Act of 2002, as amended, regarding its internal control over financial reporting. Additionally, the JOBS Act has allowed the Company the option to delay adoption of new or revised financial accounting standards until private companies are required to comply with new or revised financial accounting standards. The Company performed an annual assessment as of June 30, 2025 and will not remain eligible for EGC status as of December 31, 2025.
Indefinite-Lived Intangible Assets
Intangible assets with indefinite lives consist of IPR&D from the Company’s acquisition of Atomic Alchemy. See Note 3 — Business Combination — Atomic Alchemy for additional information. These assets are tested annually for impairment, or whenever events or circumstances indicate that the carrying amount may not be recoverable, until completion or abandonment of research and development efforts associated with the projects. If potential impairment is identified, the process of evaluating the potential impairment of these assets involves significant judgment regarding estimates of the future cash flows associated with each asset. Upon successful completion of each project, the Company makes a determination as to the then remaining useful life of the intangible asset and begins amortization.
Goodwill
Goodwill represents the excess purchase consideration of an acquired business over the estimated fair value of the net assets acquired and is not amortized. Goodwill is evaluated for impairment annually, or whenever events or circumstances indicate that the carrying amount may not be recoverable. If the carrying amount of the Company’s reportable segment exceeds its fair value, an impairment loss is recognized for any excess of the carrying amount of the reportable segment’s goodwill over the implied fair value of the goodwill.
Other Investments
Investments in which the Company does not have the ability to exercise significant influence and does not have readily determinable fair values, are recorded at cost minus impairment, plus or minus changes from observable price changes in
orderly transactions for identical or similar investments of the same issuer, in accordance with the measurement alternative described in Accounting Standards Codification (“ASC”) 321, Investments–Equity Securities. As of September 30, 2025, the Company’s sole investment is a simple agreement for future equity for $5,000 as recorded in other assets on the condensed consolidated balance sheets.
As part of the Company’s policy to maximize return on strategic investment opportunities, while preserving capital and limiting downside risk, the Company may at times enter into equity investments or simple agreements for future equity. The nature and timing of the Company’s investments will depend on available capital at any particular time and the investment opportunities identified and available to the Company. However, the Company generally does not make investments for speculative purposes and does not intend to engage in the business of making other investments.
Restatement
As disclosed in Item 9-B in the Company’s Form 10-K for the fiscal year ended December 31, 2024, as filed with the SEC on March 24, 2025, the Company has corrected the accompanying unaudited condensed consolidated financial statements for the nine months ended September 30, 2024 and applicable footnotes to decrease the change in fair value of simple agreements for future equity (“SAFEs”) to investors by $2,056 from amounts previously reported. Management determined this was immaterial to previously issued financial statements.
Recently Adopted Accounting Standards
In March 2024, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2024-02, Codification Improvements - Amendments to Remove References to the Concept Statements. This standard amends the Codification to remove references to various concepts statements and impacts a variety of topics in the Codification. The amendments apply to all reporting entities within the scope of the affected accounting guidance, but in most instances the references removed are extraneous and not required to understand or apply the guidance. Generally, the amendments in this standard are not intended to result in significant accounting changes for most entities. The standard is effective January 1, 2025 and was adopted by the Company on January 1, 2025. The adoption of ASU 2024-02 did not have a material impact on the Company as there are no references to concept statements.
Recently Issued and Not Adopted Accounting Standards
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which will require the Company to disclose specified additional information in its income tax rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. ASU 2023-09 will also require the Company to disaggregate its income taxes paid disclosure by federal, state and foreign taxes, with further disaggregation required for significant individual jurisdictions. The provisions of ASU 2023-09 are effective for annual periods beginning after December 15, 2024; early adoption is permitted using either a prospective or retrospective transition method. The Company expects ASU 2023-09 to require additional disclosures in the notes to its condensed consolidated financial statements.
In November 2024, the FASB issued ASU 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which will require disaggregated disclosures in the notes to the financial statements of certain categories of expenses, including purchases of inventory, employee compensation, and depreciation and amortization, that are included in expense line items within the statement of operations. ASU 2024-03 will be applied prospectively; however, retrospective application is permitted. ASU 2024-03, as clarified in ASU 2025-01, Clarifying the Effective Date, requires public business entities to adopt the guidance in annual reporting periods beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is evaluating the impact of ASU 2024-03 on its disclosures in the notes to its financial statements.
3.Business Combinations
Atomic Alchemy
On February 28, 2025 (the “Acquisition Date”), the Company acquired Atomic Alchemy’s common stock in a business combination for its radioisotope business located in the United States. The purchase price of $28,424 was comprised of (i) a cash portion of $900, net of cash acquired, paid at the Acquisition Date to certain Atomic Alchemy equity holders for
their respective portion of the consideration, and (ii) the issuance of 820,840 shares of the Company’s common stock representing stock consideration in exchange of Atomic Alchemy’s common stock. At the Acquisition Date, the Company’s common stock public trading price of $33.39 per share was used to measure the stock consideration of $27,408.
In connection with the business combination, the Company issued 274,339 shares of its common stock, subject to certain lock-up provisions, vesting conditions, and substantial risk of forfeiture, representing postcombination services, pursuant to an employment agreement and vesting agreement.
The composition of the preliminary purchase price is as follows:
| | | | | |
| Cash | $ | 1,016 | |
| Common stock | 27,408 | |
| Total purchase consideration | $ | 28,424 | |
The Company incurred $332 in transaction costs related to the acquisition, which primarily consisted of legal and accounting expenses. The acquisition-related expenses were recorded in general and administrative expenses on the condensed consolidated statements of operations.
The estimated fair values of assets acquired and liabilities assumed are preliminary. The Company continues to gather information to properly identify and measure all acquired assets and liabilities as of the Acquisition Date. This includes evaluating certain tax-related items such as net operating losses, carryover tax basis, and uncertain tax positions, which remain open pending finalization of the tax return for the period including the acquisition. These amounts remain provisional and may be adjusted retrospectively once additional information is obtained. The preliminary purchase price allocation resulted in the following amounts being allocated to the assets acquired and liabilities assumed at the Acquisition Date based upon their respective fair values as summarized below:
| | | | | |
| Cash | $ | 116 | |
| Prepaid expenses | 99 | |
| Property and equipment | 40 | |
| Operating lease right-of-use assets | 19 | |
| Indefinite-lived intangible assets | 27,500 | |
| Goodwill | 6,720 | |
| Operating lease liability | (19) | |
| Other current liabilities | (268) | |
| Deferred tax liabilities | (5,783) | |
Net assets acquired | $ | 28,424 | |
The Company utilized an independent appraisal firm to assist in the determination of the fair values of the assets acquired and liabilities assumed, which required certain significant management assumptions and estimates. The preliminary fair value of the indefinite-lived intangible assets representing IPR&D were valued using a pre-tax royalty for the hypothetical use of a trade name for a selected royalty rate based on a market licensing agreement bench marketing analysis.
The IPR&D consisted of two separate projects, Abundantia and Meitner. Abundantia’s preliminary fair value assigned of $4,600 is expected to produce revenue potentially as early as 2026 from the sale of purified radium and other desired radioisotopes produced via irradiation. Meitner’s preliminary fair value of $22,900 is a later stage project which will produce for sale isotopes that are prepared and irradiated into radioisotopes in Versatile Isotope Production Reactors (“VIPR”), which is a thermal pool-type nuclear reactor. Each project has a different risk profile, cash flows, and its own unique process. Abundantia is expected to produce revenue upon completion of a lab, with its fair value determined using a risk-adjusted cash flow approach applied to its potential cash flows, subject to certain possession permit required by the NRC. Meitner is expected to produce revenue once a facility is constructed, with its fair value determined using a risk-
adjusted cash flow approach applied to its cash flows, subject to approval of an application for a construction license and operating license by the NRC. There was no estimated useful life assigned given the assets are IPR&D.
The excess of the purchase price over the fair value amounts assigned to the assets acquired and liabilities assumed represents goodwill from the acquisition. Goodwill is recorded as a noncurrent asset that is not amortized but is subject to an annual review for impairment. Goodwill is not deductible for tax purposes.
The results of operations of Atomic Alchemy are included in the unaudited condensed consolidated financial statements beginning on the Acquisition Date. For the three and nine months ended September 30, 2025, the condensed consolidated statements of operations include no revenue and an immaterial amount of loss from operations for Atomic Alchemy. The Company has not presented supplemental pro forma revenue (as no revenue has been generated) and earnings of the combined business as the acquisition of Atomic Alchemy is not material to the Company’s unaudited condensed consolidated financial statements.
Recapitalization
On May 9, 2024, in connection with the Recapitalization, the Company issued 43,099,811 shares of its common stock in accordance with the Merger Agreement (consisting of 12,500,000 shares representing the AltC founder shares that were subject to forfeiture pursuant to certain vesting events, all of which was vested as of December 31, 2024, 1,450,000 shares issued in exchange for AltC private placement shares, and 29,149,811 shares to the AltC public stockholders that represented the common stock subject to redemption held by the AltC stockholders immediately before the closing), for the net assets from the Recapitalization totaling $260,860, as reflected on the condensed consolidated statement of stockholders' equity (deficit) for the three and nine months ended September 30, 2024.
In connection with the Recapitalization, the Company issued 8,407,894 shares of its common stock upon conversion of the SAFEs reflecting a change in fair value upon conversion totaling $84,138, as reflected on the condensed consolidated statement of stockholders’ equity (deficit) for the three and nine months ended September 30, 2024.
4.Balance Sheet Components
Prepaid and Other Current Assets
Prepaid and other current assets are summarized as follows:
| | | | | | | | | | | |
| |
| September 30, 2025 (unaudited) | | December 31, 2024 |
| Prepaid expense | $ | 4,773 | | | $ | 2,119 | |
| Cost-share receivables | 518 | | | 600 | |
| Accrued interest receivable | 4,717 | | | 1,138 | |
| Refundable deposit | 125 | | | 125 | |
| Other | 46 | | | 143 | |
| Total prepaid and other current assets | $ | 10,179 | | | $ | 4,125 | |
Prepaid expenses include prepaid consulting fees, insurance premiums, rent, and other charges. Cost-share receivables refer to the monetary assets obtained by the Company through several research and development cost-share projects related to nuclear recycling technology awarded by the DOE’s Advanced Research Projects Agency – Energy (“ARPA-E”). Accrued interest receivables represent interest from marketable debt securities earned and not received. Refundable deposit represents an advance payment for the grant of a right to purchase certain land, subject to certain conditions.
Prepaid expenses are amortized over the straight-line method over the contract term. Cost-share receivables are recorded as eligible costs are incurred. The refundable deposit will either be applied to the final purchase price of the land or refunded no later than December 31, 2025.
Property and Equipment, Net
Property and equipment, net are summarized as follows:
| | | | | | | | | | | |
| As of |
| September 30, 2025 (unaudited) | | December 31, 2024 |
| Computers and equipment | $ | 366 | | | $ | 366 | |
| Furniture, fixtures and machinery | 256 | | | 146 | |
| Software | 1,020 | | | 1,020 | |
| Leasehold improvements | 62 | | | 45 | |
| Total property and equipment, gross | 1,704 | | | 1,577 | |
| Less accumulated depreciation and amortization | (748) | | | (375) | |
| Construction in progress | 10,530 | | | — | |
| Total property and equipment, net | $ | 11,486 | | | $ | 1,202 | |
Included in property, plant, and equipment is construction in progress. Costs related to construction of capital projects are accumulated in construction in progress until the project is complete, as well as equipment that is not yet placed in service. A construction project is considered substantially complete upon the cessation of construction and development activities. Once the project is substantially complete and ready for its intended use these costs will be amortized over the asset’s estimated useful life.
Depreciation and amortization expenses for the three months ended September 30, 2025 and 2024 totaled $124 and $68, respectively. Depreciation and amortization expenses for the nine months ended September 30, 2025 and 2024 of $373 and $180, respectively.
Accrued Expenses and Other
Accrued expenses and other are summarized as follows:
| | | | | | | | | | | |
| As of |
| September 30, 2025 (unaudited) | | December 31, 2024 |
| Accrued professional fees | $ | 2,454 | | | $ | 652 | |
| Accrued payroll and bonuses | 2,318 | | | 636 | |
| Credit card liabilities | 283 | | | 261 | |
| Franchise and income taxes payable | 113 | | | 202 | |
| General accrued expenses | 5,732 | | | 134 | |
| Total accrued expenses and other | $ | 10,900 | | | $ | 1,885 | |
5.Leases
As of September 30, 2025, the Company had commercial real estate lease agreements for office space under operating leases.
The table below presents supplemental information related to the operating leases:
| | | | | | | | | | | |
| Nine Months Ended September 30, |
| 2025 | | 2024 |
| Operating lease costs during the period | $ | 646 | | | $ | 310 | |
| Cash payments included in the measurement of operating lease liabilities during the period | $ | 617 | | | $ | 153 | |
| Operating lease liabilities arising from obtaining lease right-of-use assets during the period | $ | 1,143 | | | $ | 1,185 | |
| Weighted-average remaining lease term (in months) as of period-end | 31 | | 27 |
| Weighted-average discount rate during the period | 8.88% | | 8.76% |
The Company utilizes its incremental borrowing rates on a collateralized basis, reflecting the Company’s credit quality and the term of the lease at the commencement of the lease in determining the present value of future payments since the implicit rate for the Company’s leases is not readily determinable.
Variable lease expense includes rental increases that are not fixed, such as those based on amounts paid to the lessor based on cost or consumption, such as maintenance, utilities and real estate taxes.
The components of operating lease costs were as follows:
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended September 30, | | Nine Months Ended September 30, |
| 2025 | | 2024 | | 2025 | | 2024 |
| Operating lease costs included in: | | | | | | | |
| Research and development | $ | 241 | | | $ | 87 | | | $ | 604 | | | $ | 229 | |
| General and administrative | 68 | | | 33 | | | 254 | | | 81 | |
Total operating costs (1) | $ | 309 | | | $ | 120 | | | $ | 858 | | | $ | 310 | |
(1) Month-to-month lease arrangements for the three months ended September 30, 2025 and 2024 of $62 and $37, respectively, and nine months ended September 30, 2025 and 2024 of $212 and $124, respectively, are included in the captions within operating lease costs.
The minimum lease payments below do not include nonlease components, which are contractual obligations under the Company’s lease, but are not fixed and can fluctuate from year to year and are expensed as incurred. Nonlease components charges for the three months ended September 30, 2025 and 2024 of $173 and $14, respectively, and nine months ended September 30, 2025 and 2024 of $268 and $55, respectively, are included in operating expenses on the condensed consolidated statements of operations.
Maturities of the operating lease liabilities are summarized as follows as of September 30, 2025:
| | | | | |
| Remaining 2025 | $ | 245 | |
| 2026 | 990 | |
| 2027 | 203 | |
| 2028 | 191 | |
| 2029 | 199 | |
| Thereafter | 34 | |
| Minimum lease payments | 1,862 | |
| Less imputed interest | (201) | |
| Present value of operating lease liabilities | $ | 1,661 | |
| Current portion of operating lease liabilities | $ | 880 | |
| Noncurrent portion of operating lease liabilities | 781 | |
| Total operating lease liabilities | $ | 1,661 | |
6.Financial Instruments
The following tables show the Company’s cash, cash equivalents, and marketable debt securities by significant investment category:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| As of September 30, 2025 |
| Amortized Cost | | Unrealized Gains | | Unrealized Losses (1) | | Fair Value | | Cash and Cash Equivalents | | Current Marketable Securities | | Noncurrent Marketable Securities |
| Cash | $ | — | | | $ | — | | | $ | — | | | $ | — | | | $ | 7,800 | | | $ | — | | | $ | — | |
| Level 1: | | | | | | | | | | | | | |
| Money market funds | — | | | — | | | — | | | — | | | 402,241 | | | — | | | — | |
| U.S. Treasury securities | 619,790 | | | 2,584 | | | (124) | | | 622,250 | | | — | | | 360,287 | | | 261,963 | |
| Subtotal | 619,790 | | | 2,584 | | | (124) | | | 622,250 | | | 402,241 | | | 360,287 | | | 261,963 | |
Level 2 (2): | | | | | | | | | | | | | |
| Commercial paper | 150,156 | | | 1,116 | | | — | | | 151,272 | | | — | | | 151,272 | | | — | |
| Total | $ | 769,946 | | | $ | 3,700 | | | $ | (124) | | | $ | 773,522 | | | $ | 410,041 | | | $ | 511,559 | | | $ | 261,963 | |
(1) There was no allowance for expected credit losses on available-for-sale marketable debt securities as of September 30, 2025 as the unrealized losses were deemed to be temporary in nature.
(2) The valuation techniques used to measure the fair values of the Company’s Level 2 financial instruments, which generally have counterparties with high credit ratings, are based on quoted market prices or model-driven valuations using significant inputs derived from or corroborated by observable market data.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| As of December 31, 2024 |
| Amortized Cost | | Unrealized Gains | | Unrealized Losses (1) | | Fair Value | | Cash and Cash Equivalents | | Current Marketable Securities | | Noncurrent Marketable Securities |
| Cash | $ | — | | | $ | — | | | $ | — | | | $ | — | | | $ | 3,020 | | | $ | — | | | $ | — | |
| Level 1: | | | | | | | | | | | | | |
| Money market funds | — | | | — | | | — | | | — | | | 94,112 | | | — | | | — | |
| U.S. Treasury securities | 156,040 | | | 1,688 | | | (6) | | | 157,722 | | | — | | | 110,249 | | | 47,473 | |
| Subtotal | 156,040 | | | 1,688 | | | (6) | | | 157,722 | | | 94,112 | | | 110,249 | | | 47,473 | |
Level 2 (2): | | | | | | | | | | | | | |
| Commercial paper | 19,902 | | | 531 | | | — | | | 20,433 | | | — | | | 20,433 | | | — | |
| Total | $ | 175,942 | | | $ | 2,219 | | | $ | (6) | | | $ | 178,155 | | | $ | 97,132 | | | $ | 130,682 | | | $ | 47,473 | |
(1) There was no allowance for expected credit losses on available-for-sale marketable debt securities as of December 31, 2024 as the unrealized losses were deemed to be temporary in nature.
(2) The valuation techniques used to measure the fair values of the Company’s Level 2 financial instruments, which generally have counterparties with high credit ratings, are based on quoted market prices or model-driven valuations using significant inputs derived from or corroborated by observable market data.
The following table shows the fair value of the Company’s marketable debt securities, by contractual maturity, as of September 30, 2025:
| | | | | |
| Due within 1 year | $ | 511,559 | |
| Due after 1 year through 5 years | 261,963 | |
| Total fair value | $ | 773,522 | |
7.Simple Agreements for Future Equity
The Company issued SAFEs prior to the Recapitalization, where the SAFEs allowed investors to purchase equity at a negotiated price at the time of each investor’s entry into such agreement with each investor receiving equity in the future with no set time for conversion. The SAFEs converted in connection with the Recapitalization. Prior to the conversion, the SAFEs were classified as a liability under ASC 480, Distinguishing Liabilities from Equity.
No SAFEs were issued during the nine months ended September 30, 2025. During the nine months ended September 30, 2024, the Company issued SAFEs in exchange for aggregate cash proceeds of $10,232.
Fair Value Measurements
Prior to the SAFEs conversion, they were measured at fair value on a recurring basis using significant unobservable inputs based upon a three-tier hierarchy under the authoritative guidance (Level 3) at each reporting period-end, with changes in the fair value recognized on the condensed consolidated statements of operations. The change in fair value during the three and nine months ended September 30, 2024 was $0 and $27,864, respectively.
8.Right of First Refusal Liability
On February 16, 2024, the Company entered into a letter of intent (the “LOI”) with an unrelated third party (the “third party”) for the purchase of power from the Company’s planned powerhouses to serve certain data centers in the U.S. on a 20-year timeline, and at a rate to be formally specified in one or more future Power Purchase Agreement(s) (each a “PPA”) (subject to the requirement that the price meets the market rate, discount and most favored nation terms contained in the agreement). In addition, the third party will have the right to renew and extend PPAs for additional 20-year terms.
The LOI provides for the third party to have a continuing right of first refusal for a period of thirty-six (36) months following its execution to purchase energy output produced by certain powerhouses developed by the Company in the U.S., subject to certain provisions and excluded powerhouses, for power capacity of no less than 100 MWe of energy output and up to cumulative maximum of 500 MWe of total energy output (the “ROFR”). In exchange for the ROFR and other rights contained in the LOI, in March 2024, the third party paid the Company $25,000 (the “Payment”). In connection with the Payment, the Company agreed to supply power at a discount to the most favored nation pricing that the Company is required to provide to the third party in a future PPA (location to be determined); provided, that pricing set out in a PPA will include an additional discount if needed such that the total savings against most favored nation pricing over the course of the PPA is equivalent to the Payment. The Payment is effectively a nonrefundable upfront payment that will be attributed to future power delivery. The third party can assign its rights under the LOI, in whole or in part, at any time. As of September 30, 2025, the outstanding balance under the right of first refusal liability was $25,000, as reflected on the condensed consolidated balance sheets.
9.Stockholders’ Equity
Pursuant to the Second Amended and Restated Certificate of Incorporation of the Company, the Company is authorized to issue 501,000,000 shares of all classes of capital stock consisting of (i) 500,000,000 shares of common stock, par value of $0.0001 per share, and (ii) 1,000,000 shares of preferred stock, par value of $0.0001 per share. Subject to the special rights of the holders of any outstanding series of preferred stock, the number of shares of preferred stock may be increased or decreased (but not below the number of shares then outstanding) by affirmative vote of the holders of a majority of the stock of the Company entitled to vote. There are no shares of preferred stock issued and outstanding.
Equity ATM Program
ATM Program – On June 2, 2025, the Company entered into a sales agreement with Goldman Sachs & Co. LLC, BofA Securities, Inc., B. Riley Securities, Inc., and TD Securities (USA) LLC (the “Sales Agents”) pursuant to which the Company may offer and sell, from time to time and at its sole discretion, shares of the Company’s Class A common stock (“common stock”) up to an aggregate gross sales price of $400,000 through the Sales Agents in an “at-the-market” offering (the “ATM Program”). Under the ATM Program, the Company agreed to pay Sales Agents commissions at a rate equal to 2.5% of the aggregate gross proceeds from each sale of shares. From August 2, 2025 to August 27, 2025, the Company sold 5,458,953 shares of its common stock through the Sales Agents at an average price of $73.27 per share, resulting in aggregate gross proceeds of $400,000.
ATM Increase – Under its existing ATM Program the Company filed a new prospectus supplement on September 3, 2025, increasing the aggregate offering amount by up to $139,999, bringing the total potential aggregate gross proceeds under the updated ATM Program to approximately $539,999. From September 5, 2025 to September 11, 2025, the Company sold 1,925,066 shares of its common stock through the Sales Agents at an average price of $72.72 per share, resulting in aggregate gross proceeds of $139,999. No additional shares will be sold under this ATM Program unless an additional prospectus supplement is filed.
During the three and nine months ended September 30, 2025, the Company offered and sold 7,384,019 shares of its common stock through the ATM Program for net proceeds of $526,499 (net of Sales Agents commissions of $13,500) and
other issuance costs of $372 payable by the Company representing $526,127 as reflected on the condensed consolidated statements of stockholders’ equity.
Common Stock Public Offering – On June 16, 2025, the Company raised gross proceeds of $460,000 pursuant to a firm commitment underwritten public offering of 7,666,667 shares of the Company’s common stock (6,666,667 shares were issued on June 16, 2025 and an additional 1,000,000 shares were issued pursuant an exercise on June 13, 2025 in connection with the underwriters’ exercise of a 30-day overallotment option in full), at a public offering price of $60.00 per share. The Company received net proceeds of $441,600 upon the sale of its common stock, (net of underwriting discounts and commissions totaling $18,400) and other offering costs of $1,498 payable by the Company, representing $440,102 as reflected on the condensed consolidated statements of stockholders’ equity.
Exercise of Stock Options – During the three and nine months ended September 30, 2025, the Company issued shares of its common stock upon the exercise of stock options totaling 1,095,737 and 2,111,835, respectively, with proceeds of $1,397 and $2,745, respectively, as reflected on the condensed consolidated statements of stockholders’ equity. During the three and nine months ended September 30, 2024, the Company issued shares of its common stock upon the exercise of stock options totaling 0 and 1,345,625, respectively, with proceeds of none and $440, respectively, as reflected on the condensed consolidated statements of stockholders’ equity (deficit).
Restricted Stock Units – The Company issued, in connection with the vesting of restricted stock units, 111,186 and 288,884 shares of the Company’s common stock during the three and nine months ended September 30, 2025, respectively, as reflected on the condensed consolidated statements of stockholders’ equity.
Common Stock Withheld for Taxes – The Company withheld 66,724 shares of its common stock upon issuance of vested restricted units, representing a payment for taxes of $1,595 during the nine months ended September 30, 2025.
10.Stock-Based Compensation
Stock-based compensation expense charged to operations is summarized as follows:
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended September 30, | | Nine Months Ended September 30, |
| 2025 | | 2024 | | 2025 | | 2024 |
| Research and development | $ | 3,510 | | | $ | 398 | | | $ | 7,712 | | | $ | 7,293 | |
| General and administrative | 5,610 | | | 1,228 | | | 15,084 | | | 3,457 | |
Total costs charged to operations (1) | $ | 9,120 | | | $ | 1,626 | | | $ | 22,796 | | | $ | 10,750 | |
(1) Nine months ended September 30, 2024 includes $7,784 of incremental costs of the modification of Legacy Oklo’s awards for the vested options-holders’ contingent right to receive a pro rata share of the Company’s common stock upon the consummation of the Recapitalization.
Effective on April 1, 2025, the Company modified a common stock award for one employee from a performance-based vesting condition to time-based vesting condition that provides for equal monthly vesting over five years. The incremental cost of $10,234 will be recognized over five years from the effective date of modification.
During the nine months ended September 30, 2025, approximately 1,860,000 shares were granted to acquire shares of the Company's common stock (consisting of restricted stock and restricted stock units) with a grant date fair value of approximately $74,000 under its stock-based compensation plan.
Unrecognized compensation expense and expected weighted-average period to be recognized related to the stock-based compensation awards as of September 30, 2025 were as follows:
| | | | | | | | | | | | | | | | | | | | |
| | Restricted Stock | | Stock Options | | Totals |
| Unrecognized compensation cost | | $ | 62,897 | | | $ | 16,359 | | | $ | 79,256 | |
| Weighted-average period over which cost is expected to be recognized (in years) | | 3.45 | | 3.78 | | 3.52 |
11.Income Taxes
The provision for income taxes in interim periods is determined using an estimate of the Company’s annual effective tax rate, adjusted for discrete items, that arise during the period. Each quarter, the Company updates its estimate of its annual effective tax rate, and if the estimated annual effective tax rate changes, the Company makes a cumulative adjustment in such period. The quarterly provision for income taxes, and estimate of the Company’s annual effective tax rate, are subject to variation due to several factors, including variability in pre-tax income (or loss), the mix of jurisdictions to which such income relates, changes in how the Company conducts business, and tax law developments.
The Company's income tax provision effective tax rate for the three months ended September 30, 2025 and 2024 was (1.6)% and (2.3)%, respectively. The Company's income tax benefit (provision) effective tax rate for the nine months ended September 30, 2025 and 2024 was 5.1% and (0.6)%, respectively.
On July 4, 2025, the One Big Beautiful Bill Act (the “Act”) was signed into law. The Act makes permanent key elements of the U.S. Tax Cuts and Jobs Act of 2017, including bonus depreciation and domestic research cost expensing beginning in tax years after December 31, 2024. The Act is not expected to have a significant impact on the Company’s tax provisions.
Due to the timing of enactment within the current reporting period, the Company has made reasonable estimates of the impact of the Act and reflected the effects in its condensed consolidated financial statements for the three and nine months ended September 30, 2025. As a result of these changes, the Company recorded a discrete income tax benefit of $99, primarily related to the reversal of previously recorded accrued federal income taxes as a result of the immediate deduction of domestic research and development expenses. The Company will continue to evaluate the impact of the Act as additional information becomes available.
The realization of deferred tax assets is dependent upon a variety of factors, including the generation of future taxable income, the reversal of deferred tax liabilities, and tax planning strategies. During the nine months ended September 30, 2025 and 2024, the Company recorded an income tax benefit (provision) and expense of $3,449 and $389, respectively, as a result of discrete items that occurred in the interim period, which caused the quarterly and year-to-date effective tax rate (“ETR”) to change from the Company’s historical annual ETR. Based upon the Company’s historical operating losses and the uncertainty of future taxable income, the Company had provided a valuation allowance against most of the deferred tax assets as of September 30, 2025 and 2024.
As of September 30, 2025 and 2024, the Company had unrecognized tax benefits related to federal research credit carryforwards, of which, if fully recognized in the future would have no impact to the ETR and would result in an adjustment to the valuation allowance. No interest and penalties related to the unrecognized tax benefits are accrued.
12.Commitments and Contingencies
Contract Commitments
The Company enters into contracts in the normal course of business with third-party contract research organizations, contract development and manufacturing organizations and other service providers and vendors. These contracts generally provide for termination on notice and, therefore, are cancellable contracts and not considered contractual obligations and commitments.
Lease Option Agreement
The Company entered into a non-assignable (unless agreed to the parties) lease option agreement (the “Lease Option”) where it agreed to pay $10 per month (the “option payment(s)”), starting on January 1, 2025 and automatically expiring on January 1, 2026 (the “option term”). In accordance with the Lease Option, the Company is required to pay $70 if the Company exercises its early termination provision, otherwise the required payments will be $120 during the option term. As consideration for the option payment(s), the Company has an exclusive right to enter into a definitive lease agreement for certain property during the option term. If a definitive lease agreement is entered into during the option term, the option payment(s) will be credited against the required lease payments under the definitive lease agreement, otherwise they will be non-refundable except for a default under the Lease Option. As of September 30, 2025, the Company has not entered into a definitive lease agreement under the Lease Option.
Contingencies
From time to time, the Company may become involved in litigation matters arising in the ordinary course of business. The Company is not a party to any legal proceedings, nor is it aware of any material pending or threatened litigation. There were no contingent liabilities as of September 30, 2025.
13.Segment Information
The Company reviews consolidated results to assess performance, make decisions, and allocates operating and capital resources of the Company as a whole; therefore, there is only one reportable segment. The Company uses net loss to allocate resources, along with using that measure as a basis for evaluating financial performance by comparing the actual results with historical budgets.
Significant segment expenses included within reported measure of segment profit or loss are research and development and general and administrative. Other segment items are represented by change in fair value of simple agreements for future equity, interest and dividend income and income taxes.
The unaudited condensed consolidated statements of operations for the three and nine months ended September 30, 2025 and 2024, reflect the significant segment expenses and other segment items, as well as the condensed consolidated balance sheets as of September 30, 2025 and December 31, 2024, for the one reportable segment.
14.Related Party Transactions
On June 25, 2025, the Company entered into an agreement under which M. Klein & Company, through its affiliate, The Klein Group LLC, will provide financial advisory and strategic services. Mr. Michael Klein, who currently serves as a director of the Company, maintains a direct controlling interest in M. Klein & Company. The advisory agreement is for a term of one year and requires the Company to pay a $250 quarterly retainer fee, in addition to other potential fees depending on the outcomes of certain transactions. During the nine months ended September 30, 2025, the Company made total payments of $250 under the agreement.
15.Subsequent Events
The Company performed an evaluation of subsequent events through the date of filing of these unaudited condensed consolidated financial statements with the SEC and determined that there have been no material subsequent events which affected, or could affect, the amounts or disclosures on the unaudited condensed consolidated financial statements.